|1.||Kremer, Thomas: 4 articles (03/2015 - 12/2009)|
|2.||Härtig, Wolfgang: 3 articles (01/2013 - 11/2010)|
|3.||Michalski, Dominik: 3 articles (01/2013 - 11/2010)|
|4.||Schmidt, K: 2 articles (10/2015 - 09/2013)|
|5.||Schmidt, Karsten: 2 articles (03/2015 - 09/2013)|
|6.||Kneser, Ulrich: 2 articles (03/2015 - 09/2013)|
|7.||Walther, Andreas: 2 articles (09/2013 - 12/2009)|
|8.||Hobohm, Carsten: 2 articles (01/2012 - 11/2010)|
|9.||Kacza, Johannes: 2 articles (01/2012 - 11/2010)|
|10.||Schneider, Dietmar: 2 articles (01/2012 - 11/2010)|
|1.||Hypertension (High Blood Pressure)
10/23/1995 - "The findings of the present study suggest that inhibition of protein kinase C does not significantly alter the formation of venular leaky sites and/or clearance of FITC-albumin during acute hypertension. "
10/23/1995 - "Permeability of the blood-brain barrier was quantitated by the formation of venular leaky sites and clearance of fluorescent-labeled albumin (FITC-albumin) before and during phenylephrine-induced acute hypertension. "
07/17/1995 - "Permeability of the blood-brain barrier was quantitated by the formation of venular leaky sites and clearance of fluorescent-labeled albumin (FITC-albumin) before and during phenylephrine-induced acute hypertension. "
07/17/1995 - "However, the magnitude of disruption of the blood-brain barrier during acute hypertension was significantly less in rats treated with L-NMMA (52% reduction in the clearance of FITC-albumin) and L-NAME (47% reduction in clearance of FITC-albumin). "
01/01/1997 - "In Groups B and C, a significant reduction in myocardial reperfusion (ww/dw: A: 5.9 +/- 0.5, B: 4.9 +/- 1.1, p < 0.02 vs A, C: 4.4 +/- 0.6, p < 0.01 vs A) edema and FITC-albumin diffusion (A: 32.8 +/- 5.9% area; B: 16.3 +/- 6.1% area, p < 0.01 vs A; C: 13.3 +/- 4.5% area, p < 0.01 vs A), especially in perimyocytic space was also observed. "
10/01/2015 - "Edema was assessed by FITC-albumin extravasation. "
09/01/2013 - "Edema was assessed by FITC-albumin extravasation. "
09/01/2013 - "Intravital microscopy was performed in mesenteric venules (0/60/120min) to asses systemic edema by FITC-albumin extravasation. "
12/01/2009 - "Edema was assessed by FITC-albumin extravasation. "
03/01/2007 - "After ischemia and reperfusion, TMZ produced a significant improvement of mechanical function associated with a reduction of CK release and FITC-albumin diffusion (P<0.001); the agent also resulted in improvement in coronary flow (at 45 min+27% vs control). "
07/30/2015 - "In all tested ischemic brains, ZO-1 fragmentation and FITC albumin extravasation was observed, starting 30 min from ischemia onset, indicating loss of BBB integrity. "
01/01/2013 - "Additional ultrastructural analyses at 5 and 25 h after ischemia induction clearly indicated FITC-albumin extravasation around vessels with intact tight junctions, while the endothelium exhibited enhanced transendothelial vesicle trafficking and signs of degeneration. "
01/01/2012 - "Four or 24 hours after ischemia onset, functional impairment was re-assessed and FITC-albumin administered intravenously obtaining leakage-related blood-brain barrier (BBB) impairment. "
01/01/2013 - "Ischemia-induced BBB breakdown was detected using intravenous injection of FITC-albumin and tight junctions in areas of FITC-albumin extravasation were subsequently studied using fluorescence and electron microscopy. "
01/01/2013 - "This study aimed to characterize the endothelial barrier antigen (EBA) as addressed by the antibody SMI-71 in a rat model of embolic stroke, considering FITC-albumin as BBB leakage marker and serum levels of BBB-associated matrix metalloproteinases (MMPs) to explore its functional significance. "
11/04/2010 - "This is the first report confirming the usefulness of simultaneously applied FITC-albumin and biotinylated rat IgG as BBB permeability markers in experimental stroke, and, specifying antibodies and lectins for multiple fluorescence labeling of NVU components. "
02/16/1994 - "A pulse of D2O and one of the other tracers was added to the perfusing liquid, and the relative concentrations of both D2O and perfluorocarbon or FITC-albumin were measured in the tumor effluent. "
02/16/1994 - "The isolated tumors were perfused with Krebs-Henseleit solution, to which could be added D2O saline and either 3% by volume F44-E (a perfluorocarbon emulsion) or 1% by weight fluorescein isothiocyanate (FITC)-albumin. "
01/01/2008 - "In subcutaneous B16 tumors in living mice, translational diffusion of 10 kDa FITC-dextran was slowed 2- to 3-fold (compared with its diffusion in water) within a depth of 0.2 mm from the tumor surface, but >10-fold beyond a depth of 1 mm. Diffusion of larger macromolecules, FITC-albumin and 500 kDa FITC-dextran, was slowed by up to 40-fold at 0.5 mm and 300-fold at 2 mm. Intratumoral collagenase (to digest collagen) or cathepsin C (to digest decorin) each increased diffusion of 10 kDa FITC-dextran by approximately 2-fold. "
|2.||Protein Kinase C
|3.||NG-Nitroarginine Methyl Ester (L-NAME)
|4.||omega-N-Methylarginine (NG Monomethyl L Arginine)
|6.||rat endothelial barrier antigen
|9.||Proteins (Proteins, Gene)
|10.||Immunoglobulin G (IgG)